Abacus Life and Lorisco Life announce the launch of PREADISAN to improve health predictions Page 1

• New partnership leverages PREADISAN, the advanced platform for health prediction using machine learning and modern proteomics
  
• Applies new big data analytics tools to the Abacus portfolio of services
• Lorisco’s risk scores enable a more personalized approach to longevity and actuarial technology to maximize value for Abacus’ customers

ORLANDO, Florida and NEW YORK, August 19, 2024 (GLOBE NEWSWIRE) —

Abacus Life, Inc. (“Abacus”) (NASDAQ: ABL), a pioneering alternative asset manager specializing in longevity and actuarial technology, and Lorisco Life LLC (“Lorisco”), a health prediction company using cutting-edge proteomics and machine learning to accurately predict health events, today announced a new partnership and product launch to revolutionize longevity-based health prediction and actuarial technology.